Literature DB >> 34132918

Experimental validation of absolute SPECT/CT quantification for response monitoring in patients with coronary artery disease.

Alina van de Burgt1, Petra Dibbets-Schneider2, Cornelis H Slump3, Arthur J H A Scholte4, Douwe E Atsma4, Lioe-Fee de Geus-Oei2,5, Floris H P van Velden2.   

Abstract

BACKGROUND: Quantitative SPECT enables absolute quantification of uptake in perfusion defects. The aim of this experimental study is to assess quantitative accuracy and precision of a novel iterative reconstruction technique (Evolution; GE Healthcare) for the potential application of response monitoring using 99mTc-tetrofosmin SPECT/CT in patients with coronary artery disease (CAD).
METHODS: Acquisitions of an anthropomorphic torso phantom with cardiac insert containing defects (with varying sizes), filled with 99mTc-pertechnetate, were performed on a SPECT/CT (Discovery 670 Pro, GE Healthcare). Subsequently, volumes of interest of the defects were manually drawn on CT to assess the recovery coefficient (RC). Bull's eye plots were composed to evaluate the uptake per segment. Finally, 99mTc-tetrofosmin SPECT/CT scans of 10 CAD patients were used to illustrate clinical application.
RESULTS: The phantom study indicated that Evolution showed convergence after 7 iterations and 10 subsets. The average repeatability deviation of all configurations was 2.91% and 3.15% (%SD mean) for filtered (Butterworth) and unfiltered data, respectively. The accuracy after post-filtering was lower compared to the unfiltered data with a mean (SD) RC of 0.63 (0.05) and 0.70 (0.07), respectively (p < 0.05). More artificial defects were found on Bull's eye plots created with the unfiltered data compared to filtered data. Eight out of ten patients showed significant changes in uptake before and after treatment (p < 0.05).
CONCLUSION: Quantification of 99mTc-tetrofosmin SPECT/CT seems feasible for CAD patients when 7 iterations (10 subsets), Butterworth post-filtering (cut off frequency 0.52 in cycles/cm, order of 5) and manual CT-delineation are applied. However, future prospective patient studies are required for clinical application.

Entities:  

Keywords:  99mTc-tetrofosmin; Coronary artery disease; Experimental validation; Phantom study; Quantitative SPECT; SPECT/CT

Year:  2021        PMID: 34132918     DOI: 10.1186/s40658-021-00393-4

Source DB:  PubMed          Journal:  EJNMMI Phys        ISSN: 2197-7364


  17 in total

1.  A multicenter evaluation of commercial attenuation compensation techniques in cardiac SPECT using phantom models.

Authors:  Michael K O'connor; Brad Kemp; Frank Anstett; Paul Christian; Edward P Ficaro; Eric Frey; Mark Jacobs; James N Kritzman; Robert A Pooley; Michael Wilk
Journal:  J Nucl Cardiol       Date:  2002 Jul-Aug       Impact factor: 5.952

2.  Underestimation of extent of ischemia by gated SPECT myocardial perfusion imaging in patients with left main coronary artery disease.

Authors:  Daniel S Berman; Xingping Kang; Piotr J Slomka; James Gerlach; Ling de Yang; Sean W Hayes; John D Friedman; Louise E J Thomson; Guido Germano
Journal:  J Nucl Cardiol       Date:  2007-07       Impact factor: 5.952

Review 3.  The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-analysis.

Authors:  Louise D Metz; Mary Beattie; Robert Hom; Rita F Redberg; Deborah Grady; Kirsten E Fleischmann
Journal:  J Am Coll Cardiol       Date:  2006-12-29       Impact factor: 24.094

4.  Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer.

Authors:  Angela Collarino; Lenka M Pereira Arias-Bouda; Renato A Valdés Olmos; Pieternel van der Tol; Petra Dibbets-Schneider; Lioe-Fee de Geus-Oei; Floris H P van Velden
Journal:  Med Phys       Date:  2018-04-10       Impact factor: 4.071

5.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

6.  CT-based SPECT attenuation correction and assessment of infarct size: results from a cardiac phantom study.

Authors:  Alexander Stephan Kroiss; Stephan Gerhard Nekolla; Georg Dobrozemsky; Thomas Grubinger; Barry Lynn Shulkin; Markus Schwaiger
Journal:  Ann Nucl Med       Date:  2017-09-21       Impact factor: 2.668

7.  Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial.

Authors:  Jan van Ramshorst; Jeroen J Bax; Saskia L M A Beeres; Petra Dibbets-Schneider; Stijntje D Roes; Marcel P M Stokkel; Albert de Roos; Willem E Fibbe; Jaap J Zwaginga; Eric Boersma; Martin J Schalij; Douwe E Atsma
Journal:  JAMA       Date:  2009-05-20       Impact factor: 56.272

8.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

9.  Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis.

Authors:  Caroline Jaarsma; Tim Leiner; Sebastiaan C Bekkers; Harry J Crijns; Joachim E Wildberger; Eike Nagel; Patricia J Nelemans; Simon Schalla
Journal:  J Am Coll Cardiol       Date:  2012-05-08       Impact factor: 24.094

10.  EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision.

Authors:  Hein J Verberne; Wanda Acampa; Constantinos Anagnostopoulos; Jim Ballinger; Frank Bengel; Pieter De Bondt; Ronny R Buechel; Alberto Cuocolo; Berthe L F van Eck-Smit; Albert Flotats; Marcus Hacker; Cecilia Hindorf; Philip A Kaufmann; Oliver Lindner; Michael Ljungberg; Markus Lonsdale; Alain Manrique; David Minarik; Arthur J H A Scholte; Riemer H J A Slart; Elin Trägårdh; Tim C de Wit; Birger Hesse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-21       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.